ICU Stock: Inside the High-Stakes $4.5B Binary Bet
ICU stock analysis: SeaStar Medical targets 50x market expansion — buy or sell 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down SeaStar Medical Holding Corporation (ICU) and its patented Selective Cytopheretic Device (SCD) targeting a massive $4.5 billion adult acute kidney injury market. With Q1 2026 revenue growing 68.9% YoY and gross margins consistently exceeding 90%, the key question for investors is whether…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.